TY - JOUR
T1 - Factors associated with Noninvasive ventilation compliance in patients with ALS/MND
AU - THE NUTRITION/NIV STUDY GROUP
AU - Jackson, C. E.
AU - Heiman-Patterson, T. D.
AU - Sherman, M.
AU - Daohai, Y. U.
AU - Kasarskis, E. J.
AU - Heiman-Patterson, Terry
AU - Sherman, Michael S.
AU - Mitchell, Melonie
AU - Sattazahn, Roseanne
AU - Scelsa, Stephen N.
AU - Imperato, Theresa
AU - Shefner, Jeremy M.
AU - Watson, Mary Lou
AU - Rollins, Yvonne
AU - Cumming, John
AU - Newman, Dan
AU - Foley, Helen
AU - Verma, Ashok
AU - Koggan, Donald
AU - Steele, Julie
AU - Jackson, Carlayne
AU - Kittrell, Pam
AU - Kasarskis, Edward J.
AU - Wells, Stephen
AU - Vanderpool, Kathryn
AU - Shrestha, Christie
AU - Taylor, Deborah
AU - Mendiondo, Marta
AU - Kryscio, Richard
AU - Healey, Margaret
AU - Sams, Marsha
AU - Thompson, Megan
AU - Mitsumoto, Hiroshi
AU - Bell, Daniel
AU - Tandan, Rup
AU - Potter, Chris
AU - Matthews, Dwight
AU - Bromberg, Mark
AU - Davis, Summer
AU - Simmons, Zachary
AU - Stephens, Beth
AU - Brothers, Ally
AU - Yu, Daohai
AU - Lu, Xiaoning
N1 - Funding Information:
This work was supported by NIH RO1 Number 3046960400 and the ALS Hope Foundation. NIV Sites–Drexel University College of Medicine: Terry Heiman-Patterson, MD, Michael Sherman, MD, Melonie Mitchell RPT, Roseanne Sattazahn RN; Beth Israel : Stephen N. Scelsa, MD, Theresa Imperato; SUNY Upstate University: Jeremy M. Shefner, MD, Ph.D, Mary Lou Watson; University of Colorado: Yvonne Rollins, MD, John Cumming; Henry Ford Hospital: Dan Newman, MD, Helen Foley; University of Miami: Ashok Verma, MD, Donald Koggan, MD, Julie Steele; University of Texas: Carlayne Jackson, MD, Pam Kittrell, RN Nutrition Sites–University of Kentucky: - Edward J. Kasarskis, MD, PhD–PI, Stephen Wells, Kathryn Vanderpool, RN, Christie Shrestha, MPH, Deborah Taylor, Marta Mendiondo, Ph.D, Richard Kryscio, Ph.D, Margaret Healey, Marsha Sams, Megan Thompson; Columbia: Hiroshi Mitsumoto, MD, FAAN, Daniel Bell; University of Vermont: Rup Tandan, MD, Chris Potter, Dwight Matthews; University of Utah: Mark Bromberg, MD, Summer Davis; Pennsylvania State University: Zachary Simmons, MD, FAAN, Beth Stephens, Ally Brothers Statistics Core–Temple University Lewis Katz School of Medicine : Daohai Yu, PhD, Xiaoning Lu MS.
Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Background: Although noninvasive ventilation (NIV) improves survival and quality of life (QOL) in ALS, use of NIV is suboptimal. Objective: To determine compliance with “early” NIV initiation, requisite for the feasibility of a large study of early NIV initiation, and examine factors impacting compliance. Methods: Seventy-three ALS participants with forced vital capacities (FVC) >50% were enrolled. Participants with FVC over 80% (Group 1) were initiated on NIV early (FVC between 80 and 85%). Participants with FVC between 50 and 80% (Group 2) started NIV at FVC between 50 and 55%. Symptom surveys, QOL scores, and NIV compliance (machine download documenting use ≥4 hours/night >60% of time) were collected following NIV initiation. Results: 53.6% of Group 1 and 50% of Group 2 were compliant 28 days following NIV initiation, with increased compliance over time. Participants who were unmarried, had lower income, lower educational attainment, or limited caregiver availability were less likely to be compliant. Bothersome symptoms in non-compliant participants included facial air pressure, frequent arousals with difficulty returning to sleep, and claustrophobia. Both compliant and noncompliant participants felt improved QOL with NIV; improvement was significantly greater in compliant participants. Conclusions: These data suggest ALS patients can comply with NIV early in their disease, and potentially benefit as evidenced by improved QOL scores, supporting both feasibility and need for a study comparing early versus late NIV initiation. Moreover, modifiable symptoms were identified that could be optimized to improve compliance. Further studies are needed to determine the impact of “early” intervention on survival and QOL.
AB - Background: Although noninvasive ventilation (NIV) improves survival and quality of life (QOL) in ALS, use of NIV is suboptimal. Objective: To determine compliance with “early” NIV initiation, requisite for the feasibility of a large study of early NIV initiation, and examine factors impacting compliance. Methods: Seventy-three ALS participants with forced vital capacities (FVC) >50% were enrolled. Participants with FVC over 80% (Group 1) were initiated on NIV early (FVC between 80 and 85%). Participants with FVC between 50 and 80% (Group 2) started NIV at FVC between 50 and 55%. Symptom surveys, QOL scores, and NIV compliance (machine download documenting use ≥4 hours/night >60% of time) were collected following NIV initiation. Results: 53.6% of Group 1 and 50% of Group 2 were compliant 28 days following NIV initiation, with increased compliance over time. Participants who were unmarried, had lower income, lower educational attainment, or limited caregiver availability were less likely to be compliant. Bothersome symptoms in non-compliant participants included facial air pressure, frequent arousals with difficulty returning to sleep, and claustrophobia. Both compliant and noncompliant participants felt improved QOL with NIV; improvement was significantly greater in compliant participants. Conclusions: These data suggest ALS patients can comply with NIV early in their disease, and potentially benefit as evidenced by improved QOL scores, supporting both feasibility and need for a study comparing early versus late NIV initiation. Moreover, modifiable symptoms were identified that could be optimized to improve compliance. Further studies are needed to determine the impact of “early” intervention on survival and QOL.
UR - http://www.scopus.com/inward/record.url?scp=85113360064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113360064&partnerID=8YFLogxK
U2 - 10.1080/21678421.2021.1917617
DO - 10.1080/21678421.2021.1917617
M3 - Article
C2 - 34348541
AN - SCOPUS:85113360064
VL - 22
SP - 40
EP - 47
JO - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
JF - Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
SN - 2167-8421
IS - S1
ER -